Clinical Trial Update: Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine, carboplatin, and bevacizumab for gastroesophageal junction and gastric cancer has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Paraplatin (Carboplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: Stanford University | Conditions: Stomach Cancer, Gastric (Stomach) Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-09-18